Mary Cromwell

Mary Cromwell began her career at Genentech in 1989 in the Pharmaceutical Development group where she developed formulations for a number of molecules in various stages of development, including Avastin®. She has held leadership positions in Protein Analytical Chemistry, Pharmaceutical Development, and Global Biologics MSAT & Global Packaging Development and has provided leadership in key initiatives including Quality by Design for Control Strategy and CMContinuum. As of June 2018, Mary became the Head of Global Quality Drug Substance. Mary received a BS in Chemistry from West Virginia University, an MS in Biophysical Chemistry from the University of California-Berkeley, and a PhD in Pharmaceutical Sciences from the University of Colorado-Denver.